Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10

被引:69
作者
Chen, Yao [1 ,2 ]
Zhang, Jinsong [1 ,2 ]
Hwang, Kwan-Ki [1 ,2 ]
Bouton-Verville, Hilary [1 ,2 ]
Xia, Shi-Mao [1 ,2 ]
Newman, Amanda [1 ,2 ]
Ouyang, Ying-Bin [3 ]
Haynes, Barton F. [1 ,2 ,4 ]
Verkoczy, Laurent [1 ,2 ,5 ]
机构
[1] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[3] Tacon Biosci, Cranbury, NJ 08512 USA
[4] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA
[5] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; PROXIMAL EXTERNAL REGION; AUTOREACTIVE B-CELLS; MU-HEAVY-CHAINS; LOW-AFFINITY; MEMBRANE; EXPRESSION; SELECTION; ENVELOPE; EPITOPE;
D O I
10.4049/jimmunol.1300770
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Developing an HIV-1 vaccine has been hampered by the inability of immunogens to induce broadly neutralizing Abs (BnAbs) that protect against infection. Previously, we used knockin (KI) mice expressing a prototypical gp41-specific BnAb, 2F5, to demonstrate that immunological tolerance triggered by self-reactivity of the 2F5 H chain impedes BnAb induction. In this study, we generate KI models expressing H chains from two other HIV-1 Abs, 4E10 (another self-/polyreactive, anti-gp41 BnAb) and 48d (an anti-CD4 inducible, nonpolyreactive Ab), and find a similar developmental blockade consistent with central B cell deletion in 4E10, but not in 48d V-H KI mice. Furthermore, in KI strains expressing the complete 2F5 and 4E10 Abs as BCRs, we find that residual splenic B cells arrest at distinct developmental stages, yet exhibit uniformly low BCR densities, elevated basal activation, and profoundly muted responses to BCR ligation and, when captured as hybridoma mAb lines, maintain their dual (gp41/lipid) affinities and capacities to neutralize HIV-1, establishing a key role for anergy in suppressing residual 2F5- or 4E10-expressing B cells. Importantly, serum IgGs from naive 2F5 and 4E10 KI strains selectively eliminate gp41 and lipid binding, respectively, suggesting B cells expressing 2F5 or 4E10 as BCRs exhibit specificity for a distinct spectrum of host Ags, including selective interactions by 2F5 BCR+ B cells (i.e., and not 4E10 BCR+ B cells) with those mimicked by its gp41 neutralization epitope.
引用
收藏
页码:1260 / 1275
页数:16
相关论文
共 70 条
[11]   EXPRESSION OF ANTI-DNA IMMUNOGLOBULIN TRANSGENES IN NON-AUTOIMMUNE MICE [J].
ERIKSON, J ;
RADIC, MZ ;
CAMPER, SA ;
HARDY, RR ;
CARMACK, C ;
WEIGERT, M .
NATURE, 1991, 349 (6307) :331-334
[12]   A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies [J].
Frey, Gary ;
Peng, Hanqin ;
Rits-Volloch, Sophia ;
Morelli, Marco ;
Cheng, Yifan ;
Chen, Bing .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (10) :3739-3744
[13]   RECEPTOR EDITING - AN APPROACH BY AUTOREACTIVE B-CELLS TO ESCAPE TOLERANCE [J].
GAY, D ;
SAUNDERS, T ;
CAMPER, S ;
WEIGERT, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (04) :999-1008
[14]   BREAKDOWN OF SELF-TOLERANCE IN ANERGIC LYMPHOCYTES-B [J].
GOODNOW, CC ;
BRINK, R ;
ADAMS, E .
NATURE, 1991, 352 (6335) :532-536
[15]  
GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421
[16]   ALTERED IMMUNOGLOBULIN EXPRESSION AND FUNCTIONAL SILENCING OF SELF-REACTIVE LYMPHOCYTES-B IN TRANSGENIC MICE [J].
GOODNOW, CC ;
CROSBIE, J ;
ADELSTEIN, S ;
LAVOIE, TB ;
SMITHGILL, SJ ;
BRINK, RA ;
PRITCHARDBRISCOE, H ;
WOTHERSPOON, JS ;
LOBLAY, RH ;
RAPHAEL, K ;
TRENT, RJ ;
BASTEN, A .
NATURE, 1988, 334 (6184) :676-682
[17]   B-1B cell development [J].
Hardy, Richard R. .
JOURNAL OF IMMUNOLOGY, 2006, 177 (05) :2749-2754
[18]   ELIMINATION FROM PERIPHERAL LYMPHOID-TISSUES OF SELF-REACTIVE LYMPHOCYTES-B RECOGNIZING MEMBRANE-BOUND ANTIGENS [J].
HARTLEY, SB ;
CROSBIE, J ;
BRINK, R ;
KANTOR, AB ;
BASTEN, A ;
GOODNOW, CC .
NATURE, 1991, 353 (6346) :765-769
[19]  
Haynes BF, 2006, EXPERT REV VACCINES, V5, P578
[20]  
Haynes Barton F., 2005, Human Antibodies, V14, P59